(Q38181851)

30 August 2017

title

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer (English)

1 reference

30 August 2017

1 reference

Guo-nan Zhang

1

1 reference

30 August 2017

Hong Liu

2

1 reference

30 August 2017

Jian-ming Huang

3

1 reference

30 August 2017

Ling Wang

4

1 reference

30 August 2017

Jing-sha Zhao

5

1 reference

30 August 2017

Chao Li

6

1 reference

30 August 2017

Kun Mi

7

1 reference

30 August 2017

Yi Zhu

8

1 reference

30 August 2017

Jia Cheng

9

1 reference

30 August 2017

Xiao Zha

10

1 reference

30 August 2017

language of work or name

English

0 references

publication date

23 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

132

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

752-757

1 reference

30 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

The resurgence of platinum-based cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Recent progress in the diagnosis and treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Ovarian cancer: strategies for overcoming resistance to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Reporting recommendations for tumor marker prognostic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Evolution of platinum resistance in high-grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Molecular mechanisms of cisplatin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.01.028

10.1016/J.YGYNO.2014.01.028

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference